These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2889299)

  • 61. Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
    Thomson AB; Mahachai V
    Clin Invest Med; 1987 May; 10(3):152-70. PubMed ID: 2887321
    [TBL] [Abstract][Full Text] [Related]  

  • 62. H+/K+-adenosine triphosphatase inhibitors. A new approach to the treatment of acid-peptic diseases.
    Lamers CB
    Digestion; 1989; 44 Suppl 1():92-5. PubMed ID: 2691316
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of omeprazole on serum gastrin levels: influence of age and sex.
    Koop H; Naumann-Koch C; Arnold R
    Z Gastroenterol; 1990 Nov; 28(11):603-5. PubMed ID: 1981116
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recent advances in the treatment of digestive diseases.
    Sun HS
    J Int Med Res; 1989; 17 Suppl 1():2A-8A. PubMed ID: 2566540
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Is there any acid peptic disease that is refractory to proton pump inhibitors?
    Bardhan KD
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():13-24, discussion 29-31. PubMed ID: 8490075
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity.
    Kato S; Ebina K; Fujii K; Chiba H; Nakagawa H
    J Pediatr; 1996 Mar; 128(3):415-21. PubMed ID: 8774516
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Omeprazole: a new drug for the treatment of acid-peptic diseases.
    Falk GW
    Cleve Clin J Med; 1991; 58(5):418-27. PubMed ID: 1934456
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists.
    Lundell L; Backman L; Ekström P; Enander LH; Fausa O; Lind T; Lönroth H; Sandmark S; Sandzén B; Unge P
    Aliment Pharmacol Ther; 1990 Apr; 4(2):145-55. PubMed ID: 1983321
    [TBL] [Abstract][Full Text] [Related]  

  • 70. H2-receptor antagonists in perspective.
    Malagelada JR; Cortot A
    Mayo Clin Proc; 1978 Mar; 53(3):184-90. PubMed ID: 24155
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [H2 receptor antagonists in the therapy of peptic ulcer disease].
    Dammann HG; Dau B; Dreyer M; Müller P; Simon B
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():136-45. PubMed ID: 2889298
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Omeprazole.
    Walan A
    Baillieres Clin Gastroenterol; 1988 Jul; 2(3):629-40. PubMed ID: 3048454
    [No Abstract]   [Full Text] [Related]  

  • 73. Drug therapy of reflux oesophagitis: an update.
    Tytgat GN
    Scand J Gastroenterol Suppl; 1989; 168():38-49. PubMed ID: 2575792
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Omeprazole. Its pharmacology and therapeutic efficacy].
    Protzer U; Holtermüller KH
    Dtsch Med Wochenschr; 1993 Feb; 118(7):230-9. PubMed ID: 8440164
    [No Abstract]   [Full Text] [Related]  

  • 75. Inhibition of gastric acid secretion and therapeutic results: is there any correlation?
    Corinaldesi R; Ghidini C; Ricci Maccarini M; Santaguida P; Fratesi E; Barbara G; Stanghellini V
    Ital J Gastroenterol; 1990; 22 Suppl 1():2-4. PubMed ID: 1983421
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Criteria for use of omeprazole in adult inpatients and outpatients.
    Lajoie C
    Clin Pharm; 1992 Feb; 11(2):177-9. PubMed ID: 1551300
    [No Abstract]   [Full Text] [Related]  

  • 77. Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists.
    Tytgat GN; Lamers CB; Hameeteman W; Jansen JM; Wilson JA
    Aliment Pharmacol Ther; 1987 Feb; 1(1):31-8. PubMed ID: 2908747
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hemolytic anemia associated with the use of omeprazole.
    Marks DR; Joy JV; Bonheim NA
    Am J Gastroenterol; 1991 Feb; 86(2):217-8. PubMed ID: 1992636
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.
    Brunner GH; Lamberts R; Creutzfeldt W
    Digestion; 1990; 47 Suppl 1():64-8; discussion 76. PubMed ID: 2093018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.